BRPI0607168A2 - terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento - Google Patents
terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamentoInfo
- Publication number
- BRPI0607168A2 BRPI0607168A2 BRPI0607168-6A BRPI0607168A BRPI0607168A2 BR PI0607168 A2 BRPI0607168 A2 BR PI0607168A2 BR PI0607168 A BRPI0607168 A BR PI0607168A BR PI0607168 A2 BRPI0607168 A2 BR PI0607168A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- present
- compositions
- preparing
- combination therapy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229930186147 Cephalosporin Natural products 0.000 abstract 1
- 108010015899 Glycopeptides Proteins 0.000 abstract 1
- 102000002068 Glycopeptides Human genes 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 abstract 1
- 229960004755 ceftriaxone Drugs 0.000 abstract 1
- 229940124587 cephalosporin Drugs 0.000 abstract 1
- 150000001780 cephalosporins Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN308DE2005 | 2005-02-14 | ||
| PCT/IN2006/000044 WO2006085337A1 (en) | 2005-02-14 | 2006-02-08 | Parenteral combination therpy for infective conditions with drug resistant bacterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607168A2 true BRPI0607168A2 (pt) | 2009-08-11 |
Family
ID=36337659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607168-6A BRPI0607168A2 (pt) | 2005-02-14 | 2006-02-08 | terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7960337B2 (https=) |
| EP (1) | EP1848413B1 (https=) |
| JP (1) | JP4918502B2 (https=) |
| KR (2) | KR20090052893A (https=) |
| CN (1) | CN101080221A (https=) |
| AU (1) | AU2006213441B2 (https=) |
| BR (1) | BRPI0607168A2 (https=) |
| CA (1) | CA2597812C (https=) |
| ES (1) | ES2482700T3 (https=) |
| MX (1) | MX2007009754A (https=) |
| NZ (1) | NZ555077A (https=) |
| PT (1) | PT1848413E (https=) |
| UA (1) | UA91208C2 (https=) |
| WO (1) | WO2006085337A1 (https=) |
| ZA (1) | ZA200704393B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080227732A1 (en) * | 2005-05-13 | 2008-09-18 | Venus Remedies Limited | Treatment and Control of Severe Infections Including Cystic Fibrosis |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| GB2459126A (en) * | 2008-04-10 | 2009-10-14 | Peter Wilson | Antimicrobial agent |
| CA2768582C (en) * | 2009-07-24 | 2017-02-14 | University Of Tennessee Research Foundation | Spectinamides as anti-tuberculosis agents |
| RU2607526C2 (ru) * | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
| US8709310B2 (en) | 2011-01-05 | 2014-04-29 | Hospira, Inc. | Spray drying vancomycin |
| ITLO20110001A1 (it) * | 2011-05-03 | 2012-11-04 | Fisiopharma Srl | Flaconi di vancomicina cloroidrata con stabilità migliorata |
| RU2491921C1 (ru) * | 2012-07-11 | 2013-09-10 | Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" | Способ лечения мастита у коров в сухостойный период |
| US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
| EP2971636A1 (en) | 2013-03-15 | 2016-01-20 | Scuderi Group, Inc. | Split-cycle engines with direct injection |
| DK2893929T3 (da) | 2013-03-15 | 2025-07-07 | Merck Sharp & Dohme Llc | Antibiotisk ceftolozansammensætninger |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US20140274993A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
| EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| BE1021242B1 (nl) * | 2014-06-11 | 2015-09-08 | Neogen N.V. | Teicoplanine lyofilisaten |
| HRP20200101T1 (hr) | 2014-11-06 | 2020-04-03 | Xellia Pharmaceuticals Aps | Glikopeptidni pripravci |
| ES3036077T3 (en) * | 2016-02-19 | 2025-09-12 | Klaus Brandenburg | Means and methods for treating bacterial infections |
| KR20190005940A (ko) | 2016-05-09 | 2019-01-16 | 셀리아 파마슈티칼즈 에이피에스 | 안정화된 글리코펩티드 항생제 제형 |
| CN107661470A (zh) * | 2016-08-29 | 2018-02-06 | 成都特兰辰亚生物科技有限公司 | 添加有萘夫西林钠治疗痢疾的组合物 |
| WO2022031830A1 (en) * | 2020-08-04 | 2022-02-10 | Harrow Ip Llc | Antibacterial compositions and methods for fabricating thereof |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| CN117899225A (zh) * | 2024-01-19 | 2024-04-19 | 芮城绿曼生物药业有限公司 | 一种增强免疫力的兽用抗菌注射剂、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775533A (en) * | 1987-02-24 | 1988-10-04 | Erbamont, Inc. | Reconstitution of dry fill cyclophosphamide |
| US6660267B1 (en) * | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| GB9500978D0 (en) * | 1995-01-19 | 1995-03-08 | Smithkline Beecham Plc | Pharmaceutical formulations |
| EP0781294A1 (de) * | 1995-07-17 | 1997-07-02 | Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. | Metallhaltige ribonukleotidpolypeptide |
| JP4142149B2 (ja) * | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | バンコマイシンの凍結乾燥製剤 |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| PL218223B1 (pl) * | 2000-06-21 | 2014-10-31 | Cubist Pharmaceuticals | Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
-
2006
- 2006-02-08 CA CA2597812A patent/CA2597812C/en not_active Expired - Fee Related
- 2006-02-08 NZ NZ555077A patent/NZ555077A/en not_active IP Right Cessation
- 2006-02-08 EP EP06711370.4A patent/EP1848413B1/en not_active Expired - Lifetime
- 2006-02-08 MX MX2007009754A patent/MX2007009754A/es active IP Right Grant
- 2006-02-08 BR BRPI0607168-6A patent/BRPI0607168A2/pt not_active IP Right Cessation
- 2006-02-08 KR KR1020097006944A patent/KR20090052893A/ko not_active Withdrawn
- 2006-02-08 PT PT67113704T patent/PT1848413E/pt unknown
- 2006-02-08 CN CNA2006800013537A patent/CN101080221A/zh active Pending
- 2006-02-08 AU AU2006213441A patent/AU2006213441B2/en not_active Ceased
- 2006-02-08 ES ES06711370.4T patent/ES2482700T3/es not_active Expired - Lifetime
- 2006-02-08 KR KR1020077012489A patent/KR20070085674A/ko not_active Ceased
- 2006-02-08 JP JP2007554741A patent/JP4918502B2/ja not_active Expired - Fee Related
- 2006-02-08 UA UAA200708619A patent/UA91208C2/ru unknown
- 2006-02-08 WO PCT/IN2006/000044 patent/WO2006085337A1/en not_active Ceased
- 2006-02-08 US US11/816,179 patent/US7960337B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 ZA ZA200704393A patent/ZA200704393B/xx unknown
-
2011
- 2011-04-27 US US13/095,665 patent/US8778873B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2597812C (en) | 2012-01-24 |
| CA2597812A1 (en) | 2006-08-17 |
| JP2008530082A (ja) | 2008-08-07 |
| KR20090052893A (ko) | 2009-05-26 |
| US7960337B2 (en) | 2011-06-14 |
| PT1848413E (pt) | 2014-07-18 |
| UA91208C2 (ru) | 2010-07-12 |
| WO2006085337B1 (en) | 2006-11-02 |
| ES2482700T3 (es) | 2014-08-04 |
| JP4918502B2 (ja) | 2012-04-18 |
| US8778873B2 (en) | 2014-07-15 |
| KR20070085674A (ko) | 2007-08-27 |
| ZA200704393B (en) | 2008-09-25 |
| EP1848413A1 (en) | 2007-10-31 |
| US20080188403A1 (en) | 2008-08-07 |
| AU2006213441B2 (en) | 2011-12-01 |
| MX2007009754A (es) | 2007-11-07 |
| CN101080221A (zh) | 2007-11-28 |
| WO2006085337A1 (en) | 2006-08-17 |
| US20110257079A1 (en) | 2011-10-20 |
| NZ555077A (en) | 2010-03-26 |
| AU2006213441A1 (en) | 2006-08-17 |
| EP1848413B1 (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607168A2 (pt) | terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento | |
| CU20070203A7 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| AR093181A1 (es) | Formulacion con contenido de enzimas digestivas bajo estable | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| NZ602675A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| MX2010002278A (es) | Farmacos antivirales para el tratamiento de una infeccion por arenavirus. | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
| JP2013541583A5 (https=) | ||
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| CO6341514A2 (es) | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica | |
| FI20095600A7 (fi) | Koostumus ihosairauksien hoitoa varten | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |